Search
Genmab A/S
GMABAdd to Watchlist
28.870USD
+0.230+0.80%
Close 07-31 16:00（ET）Quotes delayed by 15 min
17.79BMarket Cap
21.75P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Genmab A/S is 8.71, ranking 72 out of 385 in the Biotechnology & Medical Research industry. The average price target is 34.70, with a high of 48.00 and a low of 23.50.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
39.385
Target Price
+38.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Genmab A/S
GMAB
14
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Genmab A/S's expected revenue for the next quarter?
Genmab A/S's expected revenue is 1.19B.
What is Genmab A/S's price target?
Analysts forecast that Genmab A/S's price target is USD 34.70, with the highest forecast at USD 48.00 and the lowest forecast at USD 23.50.
How have Genmab A/SGMAB's recent earnings per share performed?
The market expectation was USD 0.08, while Genmab A/SGMAB's earnings per share (EPS) for the previous quarter was USD 0.05. EPS for the next quarter is expected at USD 0.34.
What is the analyst rating for Genmab A/S?
Based on the ratings of Genmab A/S's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.